Biocept Inc (BIOC)

2.09
NASDAQ : Health Care
Prev Close 2.09
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.74 / 4.29
Avg Volume 3.74M
Exchange NASDAQ
Shares Outstanding 17.50M
Market Cap 37.80M
EPS -1.90
Div & Yield N.A. (N.A)

Latest News

Biocept And Catalyst Pharmaceuticals Collaborate To Provide Liquid Biopsy Testing For Small Cell Lung Cancer To Patients With Lambert Eaton Myasthenic Syndrome (LEMS)

Biocept And Catalyst Pharmaceuticals Collaborate To Provide Liquid Biopsy Testing For Small Cell Lung Cancer To Patients With Lambert Eaton Myasthenic Syndrome (LEMS)

Catalyst Pharmaceuticals to make Biocept's Target Selector™ test available to LEMS patients in Phase III Firdapse® trial to screen for cancer every six months for up to two years, at no cost to patients

These 5 Stocks Under $10 Could Explode Up Soon

These 5 Stocks Under $10 Could Explode Up Soon

Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.

Biocept's CEO Issues Letter To Stockholders

Biocept's CEO Issues Letter To Stockholders

Highlights key accomplishments and outlines value drivers for 2017

Biocept Awarded Patent In Australia For The Use Of Antibodies In Microchannels To Capture Circulating Tumor Cells And Other Rare Cells

Biocept Awarded Patent In Australia For The Use Of Antibodies In Microchannels To Capture Circulating Tumor Cells And Other Rare Cells

Biocept further expands its global patent estate for capturing and detecting cells that are in very low abundance and that can provide important molecular information from biological fluids

Columbia University Medical Center Sponsors Clinical Study Using Biocept's Liquid Biopsy Platform To Evaluate Cerebrospinal Fluid Of Breast Cancer Patients For Metastatic Biomarkers

Columbia University Medical Center Sponsors Clinical Study Using Biocept's Liquid Biopsy Platform To Evaluate Cerebrospinal Fluid Of Breast Cancer Patients For Metastatic Biomarkers

Study designed to address the significant medical need for rapidly and accurately diagnosing brain metastases in breast cancer patients to enable better treatment decisions

Clinical Utility Of Biocept's Liquid Biopsy Platform Demonstrated In Study Results Presented At The 2016 San Antonio Breast Cancer Symposium

Clinical Utility Of Biocept's Liquid Biopsy Platform Demonstrated In Study Results Presented At The 2016 San Antonio Breast Cancer Symposium

High concordance of the Company's Target-Selector™ platform enables real-time monitoring of key biomarkers in metastatic breast cancer, and provides an alternative when tissue biopsy is not an option

Biocept Presents Robust Analytical Validation Study Results For Its PD-L1 Liquid Biopsy Test At The 17th IASLC World Conference On Lung Cancer

Biocept Presents Robust Analytical Validation Study Results For Its PD-L1 Liquid Biopsy Test At The 17th IASLC World Conference On Lung Cancer

Results demonstrate high level of analytical sensitivity and specificity for the Company's non-invasive, clinically actionable biomarker test for immunotherapy

Study Results Presented At The 2016 ESMO Annual Congress Demonstrate Leading Clinical Performance With Biocept's CtDNA Liquid Biopsy Platform Vs. Tissue Biopsy

Study Results Presented At The 2016 ESMO Annual Congress Demonstrate Leading Clinical Performance With Biocept's CtDNA Liquid Biopsy Platform Vs. Tissue Biopsy

Target Selector™ platform delivers 90% concordance and capability to rapidly detect EGFR, ALK, BRAF, and ROS1 alterations in non-small cell lung cancer patients

Biocept To Collaborate With Renowned Clinical Investigator Dr. Shilpa Gupta To Study The Utility Of Liquid Biopsy Testing In Bladder And Prostate Cancers

Biocept To Collaborate With Renowned Clinical Investigator Dr. Shilpa Gupta To Study The Utility Of Liquid Biopsy Testing In Bladder And Prostate Cancers

Observational study aimed at supporting the clinical utility of Biocept's tests for PD-L1 and androgen receptor expression

Biocept Expands Chinese Patent Protection Covering Key Technologies for Circulating Tumor Cell Capture and Analysis Used in Liquid Biopsy Tests

Biocept Expands Chinese Patent Protection Covering Key Technologies for Circulating Tumor Cell Capture and Analysis Used in Liquid Biopsy Tests

Fourteenth issued patent covers unique stain for detection of rare cells of interest including circulating tumor cells (CTCs)

Biocept To Present At Next Generation Dx Summit

Biocept To Present At Next Generation Dx Summit

Presentation to focus on identifying medically actionable biomarkers in cancer patients using liquid biopsy to analyze both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA)

Biocept Expands Distribution Of Liquid Biopsy Tests To The Philippines

Biocept Expands Distribution Of Liquid Biopsy Tests To The Philippines

Enters into agreement with HarlePhil Ventures, marking the Company's third announced international distribution partnership